Published on 5 Jan 2024 on Zacks via Yahoo Finance
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Pacira BioSciences, Inc. PCRX reported preliminary total revenues (unaudited) of $675.0 million for 2023, up 1.2% from 2022. The Zacks Consensus Estimate for the same is $671.7 million.
Pacira’s top line comprises product sales and royalty revenues. The company recognizes product revenues from the sales of its three marketed drugs — Exparel, Zilretta and iovera.
Exparel net product sales came in at $538.1 million in 2023, up 0.3% from 2022, beating our model estimate of $535.4 million.